Anti-Integrin αvβ5 Antibody, Non-Fucosylated (BioBet-1121ZP) (CAT#: BioBet-1121ZP) Datasheet

Integrin αvβ5

Integrin alphaV beta5

αVβ5 is a type of integrin that binds to matrix macromolecules and proteinases and thereby stimulates angiogenesis. However, it inhibits angiogenesis. It consists of two components, integrin alpha V and integrin beta 5.

Integrin αvβ5; Integrin alphaV beta5; Integrin α5β5

Plasma membrane

Diseases associated with ITGAV include West Nile Virus and Herpes Simplex.

Its related pathways are Integrin Pathway and Signaling by GPCR.

V (itgav) integrin is a receptor for vitronectin, cytoactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, platelet reactive protein and vWF receptors. They can recognize r-g-d sequences in a large number of ligands. ITGAV:ITGB3 It binds to fractalkine (cx3cl1) and may act as its common receptor in CX3CR1 dependent fractalkine signaling. ITGAV:ITGB3 Binding to NRG1 (via EGF domain) is crucial for NRG1 ErbB Signal. ITGAV:ITGB3 Binding with FGF1, which is essential for FGF1 signal transduction. ITGAV:ITGB3 Binding with FGF2, which is essential for FGF2 signal transduction. ITGAV:ITGB3 It binds to IGF1, which is essential for IGF1 signaling. ITGAV:ITGB3 It binds to IGF2, which is essential for IGF2 signal transduction. ITGAV:ITGB3 It binds to IL1B, which is essential for IL1B signaling. ITGAV:ITGB3 The binding of pla2g2a with pla2g2a is different from the classical ligand binding site (site 1) (site 2), which induces the conformational change of integrin and enhances the binding of ligand to site 1. ITGAV:ITGB3 and ITGAV:ITGB6 As a receptor for fibrillary protein 1 (FBN1), it mediates R - G - D - dependent cell adhesion to FBN1. Integrin alpha-v / beta-6 or alpha-v / beta-8( ITGAV:ITGB6 or ITGAV:ITGB8 )R - G - D plays a key role in the activation of transforming growth factor - 1 (TGF - beta - 1) by regulating the release of transforming growth factor - 1 (TGF - beta - 1). ITGAV:ITGB3 As a receptor for CD40LG.

1.Glycosylation at Asn74, Asn290, Asn296, Asn488, Asn554, Asn615, Asn704, Asn835, Asn851, Asn874, Asn945, Asn973, and Asn980 2.Modification sites at PhosphoSitePlus 3.Ubiquitination at Lys233 and Lys360

Protein Based Therapies
Monoclonal antibody (mAb)

IgG2b

BioBet-1121ZP

Mouse

Human

This is a function-blocking antibody against the integrin αvβ5 prevented development of lung vascular permeability in two different models of acute lung injury (ALI). The integrin αvβ5 can used as a central regulator of increased pulmonary vascular permeability and a potentially attractive therapeutic target in ALI.

Sepsis

Sepsis